AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10799375 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 17
Study 10799375 — intervention group
Group type: EXPERIMENTAL
Intervention: Young supplemented subjects
Number of subjects: 17
Study 8636459 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine
Number of subjects: 10
Study 8636459 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06% triclosan
Number of subjects: 10
Study 8636459 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 10
Study 7910120 — intervention group
Group type: EXPERIMENTAL
Intervention: (R/S)‐propafenone
Number of subjects: 0
Study 7910120 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)‐propafenone
Number of subjects: 0
Study 7910120 — intervention group
Group type: EXPERIMENTAL
Intervention: (R)‐propafenone
Number of subjects: 0
Study 7910120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7910120 — intervention group
Group type: COMPARATOR
Intervention: (R/S)‐propafenone, (S)‐propafenone, (R)‐propafenone
Number of subjects: 0
Study 2888692 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg terfenadine once daily
Number of subjects: 191
Study 2888692 — intervention group
Group type: COMPARATOR
Intervention: 60 mg terfenadine twice daily
Number of subjects: 191
Study 30829097 — intervention group
Group type: EXPERIMENTAL
Intervention: Social-media-based support through a smartphone application, text messaging, and e-mail for one menstrual cycle
Number of subjects: 64
Study 30829097 — intervention group
Group type: COMPARATOR
Intervention: Control group (no social-media-based support)
Number of subjects: 64
Study 30954146 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐PTFE membrane (test group)
Number of subjects: 20
Study 30954146 — intervention group
Group type: COMPARATOR
Intervention: No biomaterial (control group)
Number of subjects: 20
Study 30954146 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 26912729 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong for Life (SFL) resistance exercise intervention
Number of subjects: 42
Study 24255130 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (pPCI)
Number of subjects: 42
Study 24255130 — intervention group
Group type: EXPERIMENTAL
Intervention: Type III collagen synthesis
Number of subjects: 42
Study 24255130 — intervention group
Group type: EXPERIMENTAL
Intervention: Type I and III collagen synthesis markers
Number of subjects: 42
Study 22546885 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Q waves
Number of subjects: 4341
Study 22546885 — intervention group
Group type: COMPARATOR
Intervention: Symptom onset three hours or less before PCI and no baseline Q waves
Number of subjects: 4341
Study 21058605 — intervention group
Group type: EXPERIMENTAL
Intervention: Magical film
Number of subjects: 2
Study 21058605 — intervention group
Group type: COMPARATOR
Intervention: Nonmagical film
Number of subjects: 2
Study 17138832 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate ingestion (CHO) with 3 g/day L-carnitine
Number of subjects: 22
Study 17138832 — intervention group
Group type: COMPARATOR
Intervention: Control (Con) with 3 g/day L-carnitine
Number of subjects: 22
Study 15855571 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg subcutaneous exenatide b.i.d.
Number of subjects: 733
Study 15855571 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg subcutaneous exenatide b.i.d.
Number of subjects: 733
Study 15855571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 733
Study 15855571 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg and 10 microg exenatide
Number of subjects: 733
Study 15855571 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg exenatide
Number of subjects: 733
Study 15855571 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg exenatide
Number of subjects: 733
Study 12390212 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication
Number of subjects: 100
Study 12390212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 9714692 — intervention group
Group type: EXPERIMENTAL
Intervention: CD3(+) T cells
Number of subjects: 0
Study 9714692 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19(+) B lymphocytes
Number of subjects: 0
Study 9714692 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4/CD8 ratio
Number of subjects: 0
Study 9714692 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4(+)CD28(+) cells
Number of subjects: 0
Study 9714692 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DR expression
Number of subjects: 0
Study 8313807 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amino acids (Vamin 18, 250 mg protein/kg/hr) during normoglycemia
Number of subjects: 6
Study 8313807 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amino acids (Vamin 18, 250 mg protein/kg/hr) during hyperglycemia
Number of subjects: 6
Study 3136094 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 400 micrograms twice daily
Number of subjects: 71
Study 3136094 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 71
Study 30196883 — intervention group
Group type: EXPERIMENTAL
Intervention: WCC training (6-hour, single-day teacher training)
Number of subjects: 63
Study 30196883 — intervention group
Group type: EXPERIMENTAL
Intervention: WCC training plus technical assistance (TA)
Number of subjects: 63
Study 30196883 — intervention group
Group type: COMPARATOR
Intervention: Delayed training (control)
Number of subjects: 63
Study 28276086 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-but not Alone mobile-health application educational programme
Number of subjects: 250
Study 28276086 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 250
Study 26388534 — intervention group
Group type: EXPERIMENTAL
Intervention: tOPV
Number of subjects: 900
Study 26388534 — intervention group
Group type: EXPERIMENTAL
Intervention: tOPV plus IPV
Number of subjects: 900
Study 26388534 — intervention group
Group type: EXPERIMENTAL
Intervention: bOPV
Number of subjects: 900
Study 26388534 — intervention group
Group type: EXPERIMENTAL
Intervention: bOPV plus IPV
Number of subjects: 900
Study 26388534 — intervention group
Group type: EXPERIMENTAL
Intervention: bOPV plus 2IPV
Number of subjects: 900
Study 23769234 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir
Number of subjects: 2413
Study 23769234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2413
Study 21491144 — intervention group
Group type: EXPERIMENTAL
Intervention: Technosphere® Insulin (TI) inhalation powder
Number of subjects: 0
Study 18532963 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercises (PFME)
Number of subjects: 4214
Study 18532963 — intervention group
Group type: COMPARATOR
Intervention: Caesarean section delivery mode
Number of subjects: 4214
Study 18532963 — intervention group
Group type: COMPARATOR
Intervention: Urinary or faecal incontinence
Number of subjects: 4214
Study 16420706 — intervention group
Group type: EXPERIMENTAL
Intervention: MDD group
Number of subjects: 70
Study 16420706 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 12702132 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alfa-2a (IFN) regimen Group A: 6 mega units (MU) subcutaneously three times a week for 24 weeks, then 3 MU three times a week for the last 24 weeks
Number of subjects: 36
Study 12702132 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alfa-2a (IFN) regimen Group B: 9 MU daily for 2 weeks, 3 MU daily for 22 weeks, then 3 MU three times a week for the last 24 weeks
Number of subjects: 36
Study 12702132 — intervention group
Group type: COMPARATOR
Intervention: Healthy and HCV mono-infected patients (Control)
Number of subjects: 36
Study 10878501 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol infusion
Number of subjects: 9
Study 10878501 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 9
Study 8883486 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapping-enhanced counseling
Number of subjects: 320
Study 8883486 — intervention group
Group type: COMPARATOR
Intervention: Standard counseling
Number of subjects: 320
Study 1419076 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 infusion
Number of subjects: 50
Study 1419076 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (NSAID)
Number of subjects: 50
Study 1419076 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (NSAID)
Number of subjects: 50
Study 1419076 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 50
Study 1419076 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 50
Study 3831962 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal dermorphine (20 micrograms)
Number of subjects: 150
Study 3831962 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (500 micrograms)
Number of subjects: 150
Study 3831962 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular pentazocine (30 mg)
Number of subjects: 150
Study 3831962 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal dermorphine
Number of subjects: 150
Study 3831962 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine
Number of subjects: 150
Study 3831962 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular pentazocine
Number of subjects: 150
Study 31300578 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model including age, BMI, mild knee symptoms, knee problems climbing stairs, morning stiffness, postmenopausal status, and heavy work.
Number of subjects: 237
Study 30312799 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral TXA (1 g given 2 hours before incision, repeated at 3 hours and 6 hours postoperatively)
Number of subjects: 100
Study 30312799 — intervention group
Group type: COMPARATOR
Intervention: IV TXA (1 g administered 10 minutes before incision, repeated at 3 hours and 6 hours postoperatively)
Number of subjects: 100
Study 29392030 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency thermal ablation
Number of subjects: 40
Study 29392030 — intervention group
Group type: COMPARATOR
Intervention: Microdebrider-assisted turbinoplasty
Number of subjects: 40
Study 25315598 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy-focused intervention
Number of subjects: 560
Study 25315598 — intervention group
Group type: EXPERIMENTAL
Intervention: AHL-C instrument
Number of subjects: 560
Study 22486226 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of a pharmacist to primary care teams
Number of subjects: 195
Study 22486226 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 195
Study 20427749 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D (up to 40,000 IU/day for 28 weeks, then 10,000 IU/day for 12 weeks, followed by 0 IU/day) with calcium (1,200 mg/day)
Number of subjects: 49
Study 20427749 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D (up to 40,000 IU/day)
Number of subjects: 49
Study 20427749 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving high-dose vitamin D)
Number of subjects: 49
Study 20427749 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D
Number of subjects: 49
Study 17094166 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtenstein's operation
Number of subjects: 595
Study 17094166 — intervention group
Group type: COMPARATOR
Intervention: Mesh plug repair
Number of subjects: 595
Study 17094166 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 595
Study 16095500 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor antibody titer
Number of subjects: 198
Study 16095500 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidneys from the same donor
Number of subjects: 198
Study 16095500 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidneys from donors lacking HLA C7
Number of subjects: 198
Study 12360162 — intervention group
Group type: EXPERIMENTAL
Intervention: COER-verapamil hydrochloride (240 mg titrated to 360 mg)
Number of subjects: 357
Study 12360162 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (10 mg titrated to 20 mg)
Number of subjects: 357
Study 12360162 — intervention group
Group type: COMPARATOR
Intervention: Losartan (50 mg titrated to 100 mg)
Number of subjects: 357
Study 10366224 — intervention group
Group type: EXPERIMENTAL
Intervention: ADCA type I (SCA1, SCA2, SCA3)
Number of subjects: 40
Study 10366224 — intervention group
Group type: COMPARATOR
Intervention: ADCA type II
Number of subjects: 40
Study 10366224 — intervention group
Group type: EXPERIMENTAL
Intervention: SCA1 patients with polyneuropathy
Number of subjects: 40
Study 10366224 — intervention group
Group type: EXPERIMENTAL
Intervention: SCA3/MJD patients
Number of subjects: 40
Study 7741947 — intervention group
Group type: EXPERIMENTAL
Intervention: Attended prenatal childbirth education classes
Number of subjects: 106
Study 7741947 — intervention group
Group type: COMPARATOR
Intervention: Did not attend prenatal childbirth education classes
Number of subjects: 106
Study 2202790 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal vignette describing CMF
Number of subjects: 282
Study 2202790 — intervention group
Group type: COMPARATOR
Intervention: Numeric vignette describing CMF
Number of subjects: 282
Study 2202790 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal vignette group divided into thirds based on DFS estimate
Number of subjects: 282
Study 7013303 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (cerucal, 3 x 10 mg p.o.)
Number of subjects: 0
Study 7013303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7013303 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 0
Study 7013303 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentagastrin stimulation
Number of subjects: 0
Study 31743809 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO + Gln (Gln 20 g/d for 6 d and maltodextrin 8%/200 mL for 20 min)
Number of subjects: 15
Study 31743809 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO + Gln
Number of subjects: 15
Study 31743809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31743809 — intervention group
Group type: COMPARATOR
Intervention: CHO
Number of subjects: 15
Study 30651194 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block (SSNB)
Number of subjects: 42
Study 30651194 — intervention group
Group type: COMPARATOR
Intervention: Subacromial injection (SA)
Number of subjects: 42
Study 28728560 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-oriented education and medication management intervention
Number of subjects: 0
Study 28728560 — intervention group
Group type: COMPARATOR
Intervention: Usual care treatment
Number of subjects: 0
Study 28728560 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention and control groups
Number of subjects: 0
Study 26469896 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone therapy group (n = 122 patients)
Number of subjects: 251
Study 26469896 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol therapy group (n = 129 patients)
Number of subjects: 251
Study 23694704 — intervention group
Group type: EXPERIMENTAL
Intervention: High illuminance (700 lx)
Number of subjects: 0
Study 23694704 — intervention group
Group type: COMPARATOR
Intervention: Low illuminance (150 lx)
Number of subjects: 0
Study 23694704 — intervention group
Group type: EXPERIMENTAL
Intervention: Illumination conditions (3000 K and 7100 K)
Number of subjects: 0
Study 21335510 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week lifestyle program comprising aerobic and resistance exercise, plus dietary advice
Number of subjects: 50
Study 21335510 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 50
Study 19800193 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT ON (active treatment)
Number of subjects: 262
Study 19800193 — intervention group
Group type: COMPARATOR
Intervention: CRT OFF (control treatment)
Number of subjects: 262
Study 16950955 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa husk supplement
Number of subjects: 56
Study 16950955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 14687239 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified cardiovascular risk management for 6 months
Number of subjects: 159
Study 14687239 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 159
Study 10899847 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine lot E005
Number of subjects: 155
Study 10899847 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine lot E003
Number of subjects: 155
Study 10899847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 10899847 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine lot E005 and E003
Number of subjects: 155
Study 9018017 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute dietary tryptophan depletion
Number of subjects: 16
Study 8101082 — intervention group
Group type: EXPERIMENTAL
Intervention: Broxaterol (B) at 0.75 mg
Number of subjects: 36
Study 8101082 — intervention group
Group type: EXPERIMENTAL
Intervention: Broxaterol (B) at 1.25 mg
Number of subjects: 36
Study 8101082 — intervention group
Group type: EXPERIMENTAL
Intervention: Broxaterol (B) at 2.50 mg
Number of subjects: 36
Study 8101082 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 36
Study 8101082 — intervention group
Group type: EXPERIMENTAL
Intervention: Broxaterol (B) at 1.25 mg, 3 times a day for 1 month
Number of subjects: 36
Study 3794304 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg atropine sulfate
Number of subjects: 10
Study 3794304 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg pirenzepine
Number of subjects: 10
Study 31550941 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab and short course corticosteroids (CS)
Number of subjects: 0
Study 31550941 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific BTK inhibitors
Number of subjects: 0
Study 29097487 — intervention group
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC)
Number of subjects: 40
Study 29097487 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NAC)
Number of subjects: 40
Study 26307162 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose bacillus Calmette‐Guérin (40 mg)
Number of subjects: 166
Study 26307162 — intervention group
Group type: COMPARATOR
Intervention: Standard dose bacillus Calmette‐Guérin (80 mg)
Number of subjects: 166
Study 25363101 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone plus sodium valproate
Number of subjects: 48
Study 25363101 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 48
Study 24396757 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 20 mg/kg
Number of subjects: 90
Study 24396757 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 1.0 mg/kg
Number of subjects: 90
Study 24396757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 20589598 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine combined with ziprasidone (CZ)
Number of subjects: 24
Study 20589598 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine combined with risperidone (CR)
Number of subjects: 24
Study 17396066 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-Lipoic acid and acetyl-L-carnitine
Number of subjects: 36
Study 17396066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 16344515 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 121
Study 16344515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 12162470 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam 7.5 mg, 15 mg, 30 mg
Number of subjects: 79
Study 12162470 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (Indo-ER) 75 mg once daily
Number of subjects: 79
Study 12162470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 10215212 — intervention group
Group type: EXPERIMENTAL
Intervention: Triblock-copolymer circuit (polycaprolactone-polydimethylsiloxane-polycaprolactone)
Number of subjects: 34
Study 10215212 — intervention group
Group type: COMPARATOR
Intervention: Control circuit
Number of subjects: 34
Study 7533343 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506/prednisone (double therapy)
Number of subjects: 204
Study 7533343 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506/azathioprine/prednisone (triple therapy)
Number of subjects: 204
Study 7533343 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (first cadaver transplants)
Number of subjects: 204
Study 7533343 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 204
Study 2718912 — intervention group
Group type: EXPERIMENTAL
Intervention: 330 kcal/d diet
Number of subjects: 16
Study 2718912 — intervention group
Group type: EXPERIMENTAL
Intervention: 780 kcal/d diet
Number of subjects: 16
Study 2718912 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 323086 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium dobesylate, 250 mg three times a day (period B)
Number of subjects: 36
Study 323086 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium dobesylate (period C)
Number of subjects: 36
Study 323086 — intervention group
Group type: COMPARATOR
Intervention: Placebo (period D)
Number of subjects: 36
Study 323086 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium dobesylate and placebo (period C and D)
Number of subjects: 36
Study 31558866 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine group (7.5 mg/mL ropivacaine infiltration)
Number of subjects: 146
Study 31558866 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal saline 5 mL infiltration)
Number of subjects: 146
Study 29028286 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler-guided goal-directed fluid therapy (GDFT)
Number of subjects: 0
Study 25992820 — intervention group
Group type: EXPERIMENTAL
Intervention: Calendula officinalis
Number of subjects: 51
Study 25992820 — intervention group
Group type: COMPARATOR
Intervention: Essential Fatty Acids
Number of subjects: 51